Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) targeting GD2 (4SCAR-GD2). The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognition of GD2, a surface protein expressed at high levels on many types of tumors but not on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and/or recurrent tumors.

NCT Number	NCT02992210
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Solid Tumor
Enrollment	100 participants
Start Date	2025-05-01
Primary Completion	2028-06 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-08